Funding to target G-proteins
Domainex, a privately-owned drug discovery services company, has been awarded funding to develop a new biophysical screening method for G-protein coupled receptors (GPCRs).
The company will receive £118,000 from the UK’s innovation agency, Innovate UK, to develop the screening method. This investment represents an opportunity for the company to develop a technology to accelerate the discovery of new drugs.
“Domainex is developing a new way of starting GPCR drug discovery projects by using a biophysical technique called MicroScale Thermophoresis (MST), in combination with a method developed by Professor Tim Dafforn and his team at the University of Birmingham to stabilise the receptor,” said Trevor Perrior, Chief Scientific Officer at Domainex.
“This Biomedical Catalyst Feasibility Award from Innovate UK will enable Domainex scientists to test the feasibility of using this approach on GPCRs, in order to establish a generic platform that would work for any purified GPCR without the need for stabilising mutations.”
G-protein coupled receptors (GPCRs) are proteins found on the surface of cells. They detect molecules outside the cell and consequently activate internal signalling pathways that mediate cellular responses. Despite being one of the most popular classes of investigational drug targets, with 25-30% of all marketed drugs focussing on them globally, many with untapped therapeutic potential, are yet to be identified.
Related Content
When plasma leaves the laboratory
The orbital laboratory is evolving into something more ambitious, a controlled industrial environment for producing next-generation materials, explains Ed Smith and Andrew Griffiths. …
Biosimilars and the post-patent environment
The market and frameworks for biologics and their biosimilars are growing and ever-evolving, as illustrated by the news around rheumatoid …
Britain continues to dominate European biotech investment, says BIA
The UK remained Europe’s leading national biotech market in 2025 throughout the year, accounting for nearly one third of all …
